

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-49. (Cancelled).

50. (Currently Amended) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a therapeutic agent ~~comprising a cytostatic agent, an anti-migratory agent, a cytoskeletal inhibitor, or an anti-matrix agent~~ dispersed in a polymer matrix, wherein said cytostatic amount of said therapeutic agent inhibits a vascular smooth muscle cell activity without killing the cell, and wherein said therapeutic agent is ~~not heparin, a radioisotope, a nitric oxide releasing compound, suramin, methotrexate, adriamycin, a protein kinase inhibitor, staurosporin, an antisense oligonucleotide, eolichicine, a peptidic inhibitor of a cellular factor that triggers proliferation of a smooth muscle cell or a pericyte, a growth factor inhibitor, a smooth muscle derived growth factor inhibitor, an endothelial derived growth factor inhibitor, a platelet homing receptor inhibitor, an integrin inhibitor, triazolopyrimidine, or a prostaglandin~~ a modified toxin, a TGF-beta production or activation stimulator, TGF-beta, tamoxifen, a nuclear enzyme DNA topoisomerase II inhibitor, a DNA polymerase inhibitor, an RNA polymerase inhibitor, an adenylyl guanylyl cyclase inhibitor, a superoxide dismutase inhibitor, a terminal deoxynucleotidyl-transferase, a reverse transcriptase, lovastatin, vinblastin, cytochalasins, taxol, taxotere, trichothecene, a modified diphtheria toxin, a modified ricin toxin, *Pseudomonas* exotoxin, a chemotactic factor inhibitor, a chemotactic factor receptor inhibitor, an intracellular cytoskeletal protein inhibitor, a caffeic acid derivative, nilvadipine, a steroid hormone, sphingosine, somatostatin, or N-ethylmaleimide.

51. (Cancelled).

52. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

53. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises angioplasty.

54. (Currently Amended) The method of claim 50, wherein the locally administering comprises administering the cytostatic amount of the therapeutic agent ~~eytostatic agent, anti-migratory agent, cytoskeletal inhibitor, or anti-matrix agent~~ directly to vascular smooth muscle tissue.

55. (Currently Amended) The method of claim 50, wherein the release of the cytostatic amount of the therapeutic agent ~~eytostatic agent, anti-migratory agent, cytoskeletal inhibitor, or anti-matrix agent~~ from the dosage form occurs during or after the vascular surgical procedure.

56-57. (Cancelled).

58. (Currently Amended) The method of claim 50 ~~57~~, wherein the therapeutic agent ~~eytoskeletal inhibitor~~ comprises taxol or taxotere.

59. (Previously Presented) The method of claim 50, wherein the sustained release dosage form is a microparticulate.

60-65. (Cancelled).